Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone

•R1 resection after locally advanced rectal cancer entails high recurrence rates.•Effects of induction chemotherapy have not been investigated for R1 resection only.•Induction chemotherapy plus chemoradiotherapy seem to improve local disease control.•High-risk patients should receive an intensified...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical colorectal cancer 2024-10
Hauptverfasser: Hein Nordvig, Ellen, Bergliot Grønbæk, Gull-Mai, Khalid Al-Uboody, Zahra, Lykke, Jakob, Hagen Vasehus Schou, Jakob, Østergaard Poulsen, Laurids
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Clinical colorectal cancer
container_volume
creator Hein Nordvig, Ellen
Bergliot Grønbæk, Gull-Mai
Khalid Al-Uboody, Zahra
Lykke, Jakob
Hagen Vasehus Schou, Jakob
Østergaard Poulsen, Laurids
description •R1 resection after locally advanced rectal cancer entails high recurrence rates.•Effects of induction chemotherapy have not been investigated for R1 resection only.•Induction chemotherapy plus chemoradiotherapy seem to improve local disease control.•High-risk patients should receive an intensified neoadjuvant treatment regime. Total neoadjuvant treatment (TNT) with induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) has improved long-term outcomes for patients with locally advanced rectal cancer (LARC). However, long-term outcomes have not been investigated for patients with incomplete (R1) resection separately. This study investigates overall survival (OS), disease-free survival (DFS) and local and distant recurrence rates in patients with R1 resection after preoperative treatment with ICT and CRT or CRT. From the NORD database 689 patients with LARC who received treatment between 2006 and 2017 were screened for inclusion. All patients with R1 resection were included. ICT consisted of at least 1 cycle of capecitabine and oxaliplatin (CAPOX) and was followed by radiotherapy concomitant with capecitabine. Among 46 patients with R1 resection, 27 (59%) received both ICT and CRT, and 19 (41%) patients received CRT. The 5-year OS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 37% (95% CI, 15%-59%) (CRT) (P = .25) and 5-year DFS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 32% (95% CI, 11%-53%) (CRT) (P = .22). The local recurrence rates showed a small nonstatistical significant difference in local control in the ICT group: 15% compared to 26% in the CRT group (P = .22). Distant recurrence rates were similar: 41% (ICT + CRT) versus 47% (CRT) (P = .48). There was no significant difference in OS, DFS or local and distant recurrence rates between patients who received ICT + CRT versus patients who received CRT only. The long-term effects of induction chemotherapy plus standard chemoradiotherapy have not been investigated separately for patients with R1 resection. In this study 689 patients with locally advanced rectal cancer were screened for inclusion; 46 patients with R1 resection were included. No statistical significant difference was found in overall survival, disease-free survival, or local and distant recurrence rates.
doi_str_mv 10.1016/j.clcc.2024.09.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128321526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1533002824000860</els_id><sourcerecordid>3128321526</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1525-13023b7d953ba060e4cfef6765f7f4b8cf094d59c3a2b580d9c21bc3648cbdc83</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCIlsIf4IB85JLgjzgbS1xWqxYqrVRUFXG0nLHTeuXYi50U7Z_iN-IopSfEacbvvXkjz0PoPSU1JbT9dKjBA9SMsKYmsiaEv0DnVPKuIu2meVl6wXlFCOvO0JucD6VrOaWv0RmXghJJxDn6vY_hvrqzacQ38wRxtBm7gL_pydkwZfzDTQ94H0F7f8Jb86gDWINvLUza493ySvgqeh9_uXCPb2mhciFdDHg7TIW8LAalXAczr_DuwY5xwfTxhHUwK5C0cc9oTP8Atz4G-xa9GrTP9t1TvUDfry7vdl-r_c2X6912XwEVTFSUE8b7jZGC95q0xDYw2KHdtGLYDE3fwUBkY4QErlkvOmIkMNoDb5sOegMdv0AfV99jij9nmyc1ugzWex1snLPilHWclV1tkbJVCinmnOygjsmNOp0UJWrJSR3UkpNaclJEqpJTGfrw5D_3ozXPI3-DKYLPq8CWXz46m1SGkkg5vkvlvspE9z__P7MkpwU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128321526</pqid></control><display><type>article</type><title>Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone</title><source>Access via ScienceDirect (Elsevier)</source><creator>Hein Nordvig, Ellen ; Bergliot Grønbæk, Gull-Mai ; Khalid Al-Uboody, Zahra ; Lykke, Jakob ; Hagen Vasehus Schou, Jakob ; Østergaard Poulsen, Laurids</creator><creatorcontrib>Hein Nordvig, Ellen ; Bergliot Grønbæk, Gull-Mai ; Khalid Al-Uboody, Zahra ; Lykke, Jakob ; Hagen Vasehus Schou, Jakob ; Østergaard Poulsen, Laurids</creatorcontrib><description>•R1 resection after locally advanced rectal cancer entails high recurrence rates.•Effects of induction chemotherapy have not been investigated for R1 resection only.•Induction chemotherapy plus chemoradiotherapy seem to improve local disease control.•High-risk patients should receive an intensified neoadjuvant treatment regime. Total neoadjuvant treatment (TNT) with induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) has improved long-term outcomes for patients with locally advanced rectal cancer (LARC). However, long-term outcomes have not been investigated for patients with incomplete (R1) resection separately. This study investigates overall survival (OS), disease-free survival (DFS) and local and distant recurrence rates in patients with R1 resection after preoperative treatment with ICT and CRT or CRT. From the NORD database 689 patients with LARC who received treatment between 2006 and 2017 were screened for inclusion. All patients with R1 resection were included. ICT consisted of at least 1 cycle of capecitabine and oxaliplatin (CAPOX) and was followed by radiotherapy concomitant with capecitabine. Among 46 patients with R1 resection, 27 (59%) received both ICT and CRT, and 19 (41%) patients received CRT. The 5-year OS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 37% (95% CI, 15%-59%) (CRT) (P = .25) and 5-year DFS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 32% (95% CI, 11%-53%) (CRT) (P = .22). The local recurrence rates showed a small nonstatistical significant difference in local control in the ICT group: 15% compared to 26% in the CRT group (P = .22). Distant recurrence rates were similar: 41% (ICT + CRT) versus 47% (CRT) (P = .48). There was no significant difference in OS, DFS or local and distant recurrence rates between patients who received ICT + CRT versus patients who received CRT only. The long-term effects of induction chemotherapy plus standard chemoradiotherapy have not been investigated separately for patients with R1 resection. In this study 689 patients with locally advanced rectal cancer were screened for inclusion; 46 patients with R1 resection were included. No statistical significant difference was found in overall survival, disease-free survival, or local and distant recurrence rates.</description><identifier>ISSN: 1533-0028</identifier><identifier>ISSN: 1938-0674</identifier><identifier>EISSN: 1938-0674</identifier><identifier>DOI: 10.1016/j.clcc.2024.09.003</identifier><identifier>PMID: 39510905</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>LARC ; Resection status ; Retrospective data ; Survival outcome ; Total neoadjuvant chemotherapy</subject><ispartof>Clinical colorectal cancer, 2024-10</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1525-13023b7d953ba060e4cfef6765f7f4b8cf094d59c3a2b580d9c21bc3648cbdc83</cites><orcidid>0009-0006-7525-4330</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clcc.2024.09.003$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39510905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hein Nordvig, Ellen</creatorcontrib><creatorcontrib>Bergliot Grønbæk, Gull-Mai</creatorcontrib><creatorcontrib>Khalid Al-Uboody, Zahra</creatorcontrib><creatorcontrib>Lykke, Jakob</creatorcontrib><creatorcontrib>Hagen Vasehus Schou, Jakob</creatorcontrib><creatorcontrib>Østergaard Poulsen, Laurids</creatorcontrib><title>Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone</title><title>Clinical colorectal cancer</title><addtitle>Clin Colorectal Cancer</addtitle><description>•R1 resection after locally advanced rectal cancer entails high recurrence rates.•Effects of induction chemotherapy have not been investigated for R1 resection only.•Induction chemotherapy plus chemoradiotherapy seem to improve local disease control.•High-risk patients should receive an intensified neoadjuvant treatment regime. Total neoadjuvant treatment (TNT) with induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) has improved long-term outcomes for patients with locally advanced rectal cancer (LARC). However, long-term outcomes have not been investigated for patients with incomplete (R1) resection separately. This study investigates overall survival (OS), disease-free survival (DFS) and local and distant recurrence rates in patients with R1 resection after preoperative treatment with ICT and CRT or CRT. From the NORD database 689 patients with LARC who received treatment between 2006 and 2017 were screened for inclusion. All patients with R1 resection were included. ICT consisted of at least 1 cycle of capecitabine and oxaliplatin (CAPOX) and was followed by radiotherapy concomitant with capecitabine. Among 46 patients with R1 resection, 27 (59%) received both ICT and CRT, and 19 (41%) patients received CRT. The 5-year OS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 37% (95% CI, 15%-59%) (CRT) (P = .25) and 5-year DFS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 32% (95% CI, 11%-53%) (CRT) (P = .22). The local recurrence rates showed a small nonstatistical significant difference in local control in the ICT group: 15% compared to 26% in the CRT group (P = .22). Distant recurrence rates were similar: 41% (ICT + CRT) versus 47% (CRT) (P = .48). There was no significant difference in OS, DFS or local and distant recurrence rates between patients who received ICT + CRT versus patients who received CRT only. The long-term effects of induction chemotherapy plus standard chemoradiotherapy have not been investigated separately for patients with R1 resection. In this study 689 patients with locally advanced rectal cancer were screened for inclusion; 46 patients with R1 resection were included. No statistical significant difference was found in overall survival, disease-free survival, or local and distant recurrence rates.</description><subject>LARC</subject><subject>Resection status</subject><subject>Retrospective data</subject><subject>Survival outcome</subject><subject>Total neoadjuvant chemotherapy</subject><issn>1533-0028</issn><issn>1938-0674</issn><issn>1938-0674</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v1DAQtRCIlsIf4IB85JLgjzgbS1xWqxYqrVRUFXG0nLHTeuXYi50U7Z_iN-IopSfEacbvvXkjz0PoPSU1JbT9dKjBA9SMsKYmsiaEv0DnVPKuIu2meVl6wXlFCOvO0JucD6VrOaWv0RmXghJJxDn6vY_hvrqzacQ38wRxtBm7gL_pydkwZfzDTQ94H0F7f8Jb86gDWINvLUza493ySvgqeh9_uXCPb2mhciFdDHg7TIW8LAalXAczr_DuwY5xwfTxhHUwK5C0cc9oTP8Atz4G-xa9GrTP9t1TvUDfry7vdl-r_c2X6912XwEVTFSUE8b7jZGC95q0xDYw2KHdtGLYDE3fwUBkY4QErlkvOmIkMNoDb5sOegMdv0AfV99jij9nmyc1ugzWex1snLPilHWclV1tkbJVCinmnOygjsmNOp0UJWrJSR3UkpNaclJEqpJTGfrw5D_3ozXPI3-DKYLPq8CWXz46m1SGkkg5vkvlvspE9z__P7MkpwU</recordid><startdate>20241005</startdate><enddate>20241005</enddate><creator>Hein Nordvig, Ellen</creator><creator>Bergliot Grønbæk, Gull-Mai</creator><creator>Khalid Al-Uboody, Zahra</creator><creator>Lykke, Jakob</creator><creator>Hagen Vasehus Schou, Jakob</creator><creator>Østergaard Poulsen, Laurids</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0006-7525-4330</orcidid></search><sort><creationdate>20241005</creationdate><title>Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone</title><author>Hein Nordvig, Ellen ; Bergliot Grønbæk, Gull-Mai ; Khalid Al-Uboody, Zahra ; Lykke, Jakob ; Hagen Vasehus Schou, Jakob ; Østergaard Poulsen, Laurids</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1525-13023b7d953ba060e4cfef6765f7f4b8cf094d59c3a2b580d9c21bc3648cbdc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>LARC</topic><topic>Resection status</topic><topic>Retrospective data</topic><topic>Survival outcome</topic><topic>Total neoadjuvant chemotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hein Nordvig, Ellen</creatorcontrib><creatorcontrib>Bergliot Grønbæk, Gull-Mai</creatorcontrib><creatorcontrib>Khalid Al-Uboody, Zahra</creatorcontrib><creatorcontrib>Lykke, Jakob</creatorcontrib><creatorcontrib>Hagen Vasehus Schou, Jakob</creatorcontrib><creatorcontrib>Østergaard Poulsen, Laurids</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical colorectal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hein Nordvig, Ellen</au><au>Bergliot Grønbæk, Gull-Mai</au><au>Khalid Al-Uboody, Zahra</au><au>Lykke, Jakob</au><au>Hagen Vasehus Schou, Jakob</au><au>Østergaard Poulsen, Laurids</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone</atitle><jtitle>Clinical colorectal cancer</jtitle><addtitle>Clin Colorectal Cancer</addtitle><date>2024-10-05</date><risdate>2024</risdate><issn>1533-0028</issn><issn>1938-0674</issn><eissn>1938-0674</eissn><abstract>•R1 resection after locally advanced rectal cancer entails high recurrence rates.•Effects of induction chemotherapy have not been investigated for R1 resection only.•Induction chemotherapy plus chemoradiotherapy seem to improve local disease control.•High-risk patients should receive an intensified neoadjuvant treatment regime. Total neoadjuvant treatment (TNT) with induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) has improved long-term outcomes for patients with locally advanced rectal cancer (LARC). However, long-term outcomes have not been investigated for patients with incomplete (R1) resection separately. This study investigates overall survival (OS), disease-free survival (DFS) and local and distant recurrence rates in patients with R1 resection after preoperative treatment with ICT and CRT or CRT. From the NORD database 689 patients with LARC who received treatment between 2006 and 2017 were screened for inclusion. All patients with R1 resection were included. ICT consisted of at least 1 cycle of capecitabine and oxaliplatin (CAPOX) and was followed by radiotherapy concomitant with capecitabine. Among 46 patients with R1 resection, 27 (59%) received both ICT and CRT, and 19 (41%) patients received CRT. The 5-year OS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 37% (95% CI, 15%-59%) (CRT) (P = .25) and 5-year DFS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 32% (95% CI, 11%-53%) (CRT) (P = .22). The local recurrence rates showed a small nonstatistical significant difference in local control in the ICT group: 15% compared to 26% in the CRT group (P = .22). Distant recurrence rates were similar: 41% (ICT + CRT) versus 47% (CRT) (P = .48). There was no significant difference in OS, DFS or local and distant recurrence rates between patients who received ICT + CRT versus patients who received CRT only. The long-term effects of induction chemotherapy plus standard chemoradiotherapy have not been investigated separately for patients with R1 resection. In this study 689 patients with locally advanced rectal cancer were screened for inclusion; 46 patients with R1 resection were included. No statistical significant difference was found in overall survival, disease-free survival, or local and distant recurrence rates.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39510905</pmid><doi>10.1016/j.clcc.2024.09.003</doi><orcidid>https://orcid.org/0009-0006-7525-4330</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1533-0028
ispartof Clinical colorectal cancer, 2024-10
issn 1533-0028
1938-0674
1938-0674
language eng
recordid cdi_proquest_miscellaneous_3128321526
source Access via ScienceDirect (Elsevier)
subjects LARC
Resection status
Retrospective data
Survival outcome
Total neoadjuvant chemotherapy
title Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A33%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Outcomes%20in%20Patients%20With%20Locally%20Advanced%20Rectal%20Cancer%20Following%20R1%20Resection%20After%20Either%20Induction%20Chemotherapy%20and%20Chemoradiotherapy%20or%20Chemoradiotherapy%20Alone&rft.jtitle=Clinical%20colorectal%20cancer&rft.au=Hein%20Nordvig,%20Ellen&rft.date=2024-10-05&rft.issn=1533-0028&rft.eissn=1938-0674&rft_id=info:doi/10.1016/j.clcc.2024.09.003&rft_dat=%3Cproquest_cross%3E3128321526%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128321526&rft_id=info:pmid/39510905&rft_els_id=S1533002824000860&rfr_iscdi=true